U.S., Nov. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07240662) titled 'Vorasidenib in CNS WHO Grade 2 IDH-mutant Diffuse Glioma' on Sept. 29.
Brief Summary: The goal of this prospective, observational study VIOLETA is to collect real-world data on vorasidenib treatment in a broad patient population. Though vorasidenib can be administered from 12 years old, VIOLETA focuses on adult patients with IDH1- or IDH2-mutant WHO grade 2 glioma who receive vorasidenib following surgery according to the current SmPC. Thus, VIOLETA will evaluate for the first-time treatment with vorasidenib in German clinical routine. To gain knowledge about how vorasidenib treatment affects patients' well-being, the primary object...